Oncology Medical News about allo-SCT

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Management of relapse after allo-SCT for AML and the role of second transplantation
Bone Marrow Transplantation, 10/29/09

Savani BN et al. – Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, the authors discuss the currently available approaches for relapsed AML after allo–SCT.

Exclusive Author Commentary
N Reddy and BN Savani , 10/30/09

Disease relapse following an allogeneic stem cell transplant for acute myeloid leukemia is a major cause of death. A deeper understanding of the biology of this disease, modulating immune responses and novel targeted agents deserve further discussion. Agents that are very specific to a particular target would theoretically be more beneficial at minimal disease state than rapidly progressive disease. Current data does not overwhelmingly support the use of any particular modality. The risk of relapse appears to outweigh the current use of strategies such as a second allogeneic stem cell transplants, donor lymphocyte infusions as well as reduction of immune-suppression. The future of managing disease relapse in acute leukemia following an allogeneic stem cell transplant depends on a wise combination of manipulating the immune system along with the use of target specific agents.

<< Previous
Racial differences in follow-up of abnormal mammography findings...

Next >>
A phase I study of imexon plus gemcitabine as first-line therapy...

Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia
Bone Marrow Transplantation, 10/15/09 Relevance Score: 82%

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
Bone Marrow Transplantation, 10/15/09 Relevance Score: 80%